Intellia Therapeutics Inc (NASDAQ:NTLA) saw unusually-strong trading volume on Thursday . Approximately 566,977 shares were traded during mid-day trading, an increase of 181% from the previous session’s volume of 201,584 shares.The stock last traded at $18.95 and had previously closed at $18.45.

A number of equities research analysts have weighed in on NTLA shares. Jefferies Group started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “hold” rating and a $33.00 price objective for the company. Leerink Swann started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price objective for the company. Wedbush assumed coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price objective for the company. Finally, Credit Suisse Group AG assumed coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 target price on the stock.

The stock’s 50-day moving average price is $21.81 and its 200-day moving average price is $23.96. The company’s market cap is $681.04 million.

In other Intellia Therapeutics news, Director Carl L. Gordon acquired 250,000 shares of the stock in a transaction on Wednesday, May 11th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $4,500,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Institutes For Biomed Novartis acquired 277,777 shares of the stock in a transaction on Wednesday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $4,999,986.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.